1052114-83-6

Basic information

• Product Name: 5-BroMo-4-hydroxynicotinic acid
• Synonyms: 5-BroMo-4-hydroxynicotinic acid;5-BroMo-4-hydroxypyridin-3-carboxylic acid;5-bromo-4-hydroxypyridine-3-carboxylic acid
• CAS NO: 1052114-83-6
• Molecular Formula: C₆H₄BrNO₃
• Molecular Weight: 218.00486
• Mol File: 1052114-83-6.mol

Chemical Properties

• Boiling Point: 452.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.985±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.46±0.14(Predicted)
• CAS DataBase Reference: 5-BroMo-4-hydroxynicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-4-hydroxynicotinic acid(1052114-83-6)
• EPA Substance Registry System: 5-BroMo-4-hydroxynicotinic acid(1052114-83-6)

Safety Data

• Hazardous Substances Data: 1052114-83-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-4-hydroxynicotinic acid is utilized as a key intermediate in the production of various pharmaceuticals. Its unique structure allows for the creation of a range of bioactive compounds, contributing to the development of novel treatments for a variety of health conditions.
Used in Agrochemical Development:
In the agrochemical industry, 5-Bromo-4-hydroxynicotinic acid serves as a crucial component in the synthesis of new pesticides and fungicides. Its inherent antibacterial and antifungal properties make it an effective agent in controlling plant diseases and pests, thereby enhancing crop protection and yield.
Used in Antibacterial Agents:
5-Bromo-4-hydroxynicotinic acid is employed as an antibacterial agent, leveraging its ability to combat bacterial infections. Its incorporation into pharmaceutical formulations can lead to the development of new antibiotics to address the growing challenge of antibiotic resistance.
Used in Antifungal Formulations:
Similarly, 5-BroMo-4-hydroxynicotinic acid is used in antifungal formulations to treat fungal infections. Its antifungal activity is valuable in both medical and agricultural contexts, providing a means to combat fungal pathogens that threaten human health and crop productivity.
Used in Research and Development:
5-Bromo-4-hydroxynicotinic acid is also a vital component in research and development laboratories. It is used in the synthesis and testing of new chemical entities, facilitating the discovery of innovative drugs and agrochemicals with improved efficacy and safety profiles.

InChI:InChI=1S/C7H6BrNO3/c1-12-7(11)4-2-9-3-5(8)6(4)10/h2-3H,1H3,(H,9,10)

Upstream product

• 109-72-8 n-butyllithium 
• 25813-25-6 3,5-dibromo-4-hydroxypyridine 
• 124-38-9 carbon dioxide 
• 67848-59-3 4-piperidone-3-carboxylic acid ethyl ester 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 609-70-1 4-hydroxynicotinic acid 

Downstream Products

• 1175512-08-9 methyl 5-bromo-4-oxo-1,4-dihydropyridine-3-carboxylate 
• 1449299-95-9 N-{4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-6'-fluoro-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydro-3,3'-bipyridine-5-carboxamide 

Relevant articles and documents

Preparation method of 4-methoxy-5-cynao-3-pyridinecarboxylic acid methyl ester

The invention relates to the field of pharmaceutical synthesis, in particular to a preparation method of 4-methoxy-5-cynao-3-pyridinecarboxylic acid methyl ester (shown in a formula I) and an intermediate thereof. According to the preparation method, 4-hydroxynicotinic acid is used as a starting raw material, and through the three reactions of bromination, methylation and cyano-substitution, the target product 4-methoxy-5-cynao-3-pyridinecarboxylic acid methyl ester (shown in the formula I) is prepared, wherein in the cyano-substitution step, cuprous cyanide is adopted to perform cyano-substitution which is better than substitutive synthesis through other cyano-compounds. Through the preparation method, the raw materials are easy and convenient to obtain, reaction conditions are mild, aftertreatment is simple, and therefore the preparation method is suitable for industrial production.

Preparation method of nicotinic acid derivative

The invention relates to a preparation method of a nicotinic acid derivative. The method comprises the following steps: with N-benzylpiperidine-4-keto-3-formate as a raw material, carrying out a hydrogenolysis reaction to obtain piperidine-4-keto-3-formate; performing halogenation reaction with a certain amount of a halogenation reagent to obtain 3,5-dihalogenated piperidine-4-one-3-formate or 3,5,5-trihalogenated piperidine-4-one-3-formateperforming one-pot process with different alkaline reagent for removing halogen hydride through elimination, and performing hydrolysis and performing acidification with hydrochloric to generate corresponding nicotinic acid derivatives: 4-hydroxynicotinic acid, 4-aminonicotinic acid, 4-hydroxy-5-chloronicotinic acid, 4-amino-5-chloronicotinic acid and 4-amino-5-bromonicotinic acid. The method is simple and convenient to operate, mild in condition, short in technological process, low in wastewater amount, environmentally friendly and low in cost, and green industrial production of the nicotinic acid derivative is facilitated.

Pyridone Derivatives

Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives represented by the formula (1) having various substituents or salts thereof, or crystals thereof (where R1, R2, R3, R5, R6, A, W, X and n in the formula (1) are as defined in the specification, respectively) are provided.

Discovery of pyrrolopyridine-pyridone based inhibitors of met kinase: Synthesis, X-ray crystallographic analysis, and biological activities

Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.